These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36102999)

  • 1. Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
    Proctor JR; Gartner EM; Gray TE; Davies RH
    Cancer Chemother Pharmacol; 2022 Nov; 90(5):399-408. PubMed ID: 36102999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
    Meric-Bernstam F; Beeram M; Hamilton E; Oh DY; Hanna DL; Kang YK; Elimova E; Chaves J; Goodwin R; Lee J; Nabell L; Rha SY; Mayordomo J; El-Khoueiry A; Pant S; Raghav K; Kim JW; Patnaik A; Gray T; Davies R; Ozog MA; Woolery J; Lee KW
    Lancet Oncol; 2022 Dec; 23(12):1558-1570. PubMed ID: 36400106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity.
    Weisser NE; Sanches M; Escobar-Cabrera E; O'Toole J; Whalen E; Chan PWY; Wickman G; Abraham L; Choi K; Harbourne B; Samiotakis A; Rojas AH; Volkers G; Wong J; Atkinson CE; Baardsnes J; Worrall LJ; Browman D; Smith EE; Baichoo P; Cheng CW; Guedia J; Kang S; Mukhopadhyay A; Newhook L; Ohrn A; Raghunatha P; Zago-Schmitt M; Schrag JD; Smith J; Zwierzchowski P; Scurll JM; Fung V; Black S; Strynadka NCJ; Gold MR; Presta LG; Ng G; Dixit S
    Nat Commun; 2023 Mar; 14(1):1394. PubMed ID: 36914633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
    DiPeri TP; Evans KW; Wang B; Zhao M; Akcakanat A; Raso MG; Rizvi YQ; Zheng X; Korkut A; Varadarajan K; Uzunparmak B; Dumbrava EE; Pant S; Ajani JA; Pohlmann PR; Jensen VB; Javle M; Rodon J; Meric-Bernstam F
    Cancer Discov; 2024 May; 14(5):828-845. PubMed ID: 38358339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of dosing strategy for pembrolizumab for oncology indications.
    Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
    J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
    Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
    Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin
    Quartino AL; Li H; Kirschbrown WP; Mangat R; Wada DR; Garg A; Jin JY; Lum B
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):329-340. PubMed ID: 30467591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.
    Harding JJ; Fan J; Oh DY; Choi HJ; Kim JW; Chang HM; Bao L; Sun HC; Macarulla T; Xie F; Metges JP; Ying J; Bridgewater J; Lee MA; Tejani MA; Chen EY; Kim DU; Wasan H; Ducreux M; Bao Y; Lindsey S; Bachini M; Morement H; Boyken L; Ma J; Garfin P; Pant S;
    Future Oncol; 2024 Aug; ():1-11. PubMed ID: 39114870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
    Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
    J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
    Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
    Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors.
    de Vries Schultink AHM; Bol K; Doornbos RP; Murat A; Wasserman E; Dorlo TPC; Schellens JHM; Beijnen JH; Huitema ADR
    Clin Pharmacokinet; 2020 Jul; 59(7):875-884. PubMed ID: 32006223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.
    Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y
    Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis.
    Paccaly AJ; Migden MR; Papadopoulos KP; Yang F; Davis JD; Rippley RK; Lowy I; Fury MG; Stankevich E; Rischin D
    Adv Ther; 2021 May; 38(5):2365-2378. PubMed ID: 33768419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.
    Quartino AL; Hillenbach C; Li J; Li H; Wada RD; Visich J; Li C; Heinzmann D; Jin JY; Lum BL
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):77-88. PubMed ID: 26645407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.